---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-030129"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-04-09T23:59:59+00:00"
generated_at: "2026-05-23T18:25:14.491989+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# INmune Bio presents MINDFul Phase 2 baseline data; top-line results expected June 2025

## Summary
- Poster at AD/PD conference details demographics: mean age 72.5 years, 69.2% APOE ε4 carriers.
- 64.9% of enrolled patients positive for >1 biomarker of immune dysfunction (hsCRP, ESR, HbA1C, APOE ε4).
- Trial enrolled patients with MCI or mild AD; EMACC composite used as primary cognitive endpoint.
- Screen failures driven mainly by MMSE inclusion criteria; enrollment completed November 2024.
- Top-line results from the 24-week, randomized, placebo-controlled study expected in June 2025.

## SEC filing metadata
- accession: 0001213900-25-030129
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025030129/0001213900-25-030129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025030129/ea0237701-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-030129
- JSON: https://secwatch.observer/filing/0001213900-25-030129.json
- Plain text: https://secwatch.observer/filing/0001213900-25-030129.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.